| アブストラクト | INTRODUCTION: Advancing age, comorbidity, and financial burden have been observed in chronic hepatitis B (CHB) patients globally. As Japan is leading the world in aging demographics, similar real-world data are urgently needed for its CHB population to inform all stakeholders. METHODS: This cross-sectional study characterized the demographics, comorbidities, and healthcare costs of a large Japanese real-world adult (>/=18 years) CHB patient (ICD-10: B18.1) population from the Medical Data Vision database from January 01, 2012, to December 31, 2016. Comorbidities were identified by ICD-10 codes, and the annual point prevalence and Charlson Comorbidity Index (CCI) score were calculated. Annual mean and median all-cause healthcare utilization and costs per patient were calculated. Comparison tests were conducted for CCI scores, prevalence of comorbidities, and healthcare resource utilization and costs. RESULTS: We identified 11,125 CHB patients. Between 2012 and 2016, the mean age increased from 62.0 to 65.2 years, and the percentage of those aged >/=65 years increased from 45.6% to 60.7%. The prevalence of cirrhosis remained similar (5.8% in 2012 and 5.6% in 2016, p = 0.69) while hepatocellular carcinoma decreased from 6.3% to 4.5% (p < 0.01). The prevalence of nonliver comorbidities increased (40.9-52.0% for cancer [p < 0.01], 12.1-17.7% for osteoporosis [p < 0.01], and 10.7-15.0% for renal impairment [p < 0.01]). Healthcare resource utilization and costs also increased, with a 119.3% increase in median total healthcare costs from JPY 229,143 in 2012 to 502,467 in 2016 (p < 0.01). CONCLUSIONS: The CHB population of Japan is predominantly elderly and carry a high nonliver comorbidity burden, while incurring increasing healthcare costs. |
|---|
| ジャーナル名 | Digestive diseases (Basel, Switzerland) |
|---|
| 投稿日 | 2021/3/16 |
|---|
| 投稿者 | Yotsuyanagi, Hiroshi; Kurosaki, Masayuki; Yatsuhashi, Hiroshi; Lee, I-Heng; Ng, Alvin; Brooks-Rooney, Craig; Nguyen, Mindie H |
|---|
| 組織名 | Department of Infectious Diseases and Applied Immunology, The Hospital of The;Institute of Medical Science, The University of Tokyo, Tokyo, Japan.;Department of Gastroenterology and Hepatology, Japanese Red Cross Musahino;Hospital, Tokyo, Japan.;Clinical Research Center, National Hospital Organization Nagasaki Medical Center,;Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.;Gilead Sciences Inc., Foster City, California, USA.;Costello Medical Singapore Pte Ltd, Singapore, Singapore.;Costello Medical, Boston, Massachusetts, USA.;Division of Gastroenterology and Hepatology, Stanford University Medical Center,;Palo Alto, California, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/33721872/ |
|---|
